BBBrian J. Barnes

Brian J. Barnes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brian J. Barnes has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Dennis W. Grauer

    Department of Pharmacy Practice, School of Pharmacy, The University of Kansas Medical Center

    2 shared publications
  • Jeffrey B. Kramer

    Mid-America Thoracic and Cardiovascular Surgery, The University of Kansas Medical Center

    2 shared publications
  • Patricia A. Howard

    Department of Pharmacy Practice, School of Pharmacy; Cardiovascular Division, Department of Internal Medicine, School of Medicine, The University of Kansas Medical Center

    2 shared publications
  • Andrea R. Terrell

    Department of Pathology

    1 shared publication
  • Buddhadeb Dawn

    Division of Cardiovascular Diseases; Department of Internal Medicine, School of Medicine; The University of Kansas Medical Center

    1 shared publication
  • Christopher Gerst

    Division of Emergency Medicine

    1 shared publication

Latest Publications

  • Nicardipine versus Sodium Nitroprusside for Postcardiac Surgery Hypertension: An Evaluation of Effectiveness and Postoperative Costs

    by Brian J. Barnes, Patricia A. Howard, Sue-Min Lai, Dennis W. Grauer, Jeffrey B. Kramer, Emmanuel Daon, George L. Zorn, Buddhadeb Dawn, Greg F. Muehlebach

    Background: Postoperative hypertension after cardiac surgery is associated with substantial morbidity. Both sodium nitroprusside (SNP) and nicardipine (NIC) are effective in its management. Outcomes data for NIC and SNP in persons undergoing cardiac surgery are limited, and there are no data characterizing the influence of drug choice on postoperative costs. Objective: Our aim was to compare the effectiveness of NIC versus SNP in the management of hypertension after cardiac surgery and evaluate the influence of drug choice on postoperative costs. Methods: We conducted a retrospective, cohort study using our hospital's financial and electronic medical records. Adults admitted to a cardiothoracic surgical intensive care unit after coronary artery bypass grafting (CABG) and/or valve surgery who developed hypertension requiring ≥30 minutes of NIC or SNP were included. We evaluated drug effectiveness by assessing infusion rate stability, blood pressure and heart rate, and concomitant antihypertensive agent use. Activity-based postoperative costs were compared between study groups. Results: One hundred twelve subjects were included (NIC = 72, SNP = 40). Hypertension-related demographics were balanced between the groups. NIC was associated with improved infusion rate stability that required fewer dose changes per hour (1.2 ± 1.6) versus SNP (1.7 ± 1.8) ( P = .004). Heart rates and blood pressures did not differ significantly. The number of antihypertensive medications used before and during the NIC or SNP infusions was the same. However, persons who were prescribed SNP required significantly more medications to manage blood pressure after infusions were discontinued ( P = .001). NIC use did not significantly increase postoperative cost. NIC use may be associated with cost increases in isolated CABG but with cost savings in isolated valve or combined CABG/valve surgeries; however, these differences were not statistically significant. Conclusions: Blood pressure was equally controlled using NIC or SNP. NIC was associated with improved infusion rate stability. Despite a higher acquisition cost, NIC did not significantly influence postoperative costs. Larger, prospective cost-effective analyses in surgical subgroups are needed.

  • Drug-induced arrhythmias

    by Brian J. Barnes, James M. Hollands

    The objective of this review is to characterize the mechanisms, risk factors, and offending pharmacotherapeutic agents that may cause drug-induced arrhythmias in critically ill patients. PubMed, other databases, and citation review were used to identify relevant published literature. The authors independently selected studies based on relevance to the topic. Numerous drugs have the potential to cause drug-induced arrhythmias. Drugs commonly administered to critically ill patients are capable of precipitating arrhythmias and include antiarrhythmics, antianginals, antiemetics, gastrointestinal stimulants, antibacterials, narcotics, antipsychotics, inotropes, digoxin, anesthetic agents, bronchodilators, and drugs that cause electrolyte imbalances and bradyarrhythmias. Drug-induced arrhythmias are insidious but prevalent. Critically ill patients frequently experience drug-induced arrhythmias; however, enhanced appreciation for this adverse event has the potential to improve prevention, treatment, patient safety, and outcomes in this patient population.


  • Risk-Stratified Evaluation of Amiodarone to Prevent Atrial Fibrillation After Cardiac Surgery

    by Brian J. Barnes, Erin A. Kirkland, Patricia A. Howard, Dennis W. Grauer, Michael E. Gorton, Jeffrey B. Kramer, Gregory F. Muehlebach, William A. Reed


  • Osmol Gap as a Surrogate Marker for Serum Propylene Glycol Concentrations in Patients Receiving Lorazepam for Sedation

    by Brian J. Barnes, Christopher Gerst, Jennifer R. Smith, Andrea R. Terrell, Michael E. Mullins

    Study Objectives. To correlate serum propylene glycol concentration with osmol gap, serum lactate concentration, and amount of propylene glycol administered to mechanically ventilated patients receiving continuous infusions of lorazepam (80% propylene glycol by weight), and to characterize the prevalence of hyperosmolality and range of serum propylene glycol concentrations in this patient population.Design. Prospective, controlled, observational study.Setting. Adult surgical and cardiothoracic intensive care units (ICUs) of a 1200‐bed, urban, tertiary care, teaching hospital.Patients. Sixty‐four consecutively enrolled intensive care patients requiring mechanical ventilation and pharmacologic sedation.Intervention. Thirteen patients received continuous infusions of high‐dose lorazepam (≥ 6 mg/hr) for a minimum of 36 hours, and 26 received continuous infusions of low‐dose lorazepam (2–5.99 mg/hr) for 36 hours. Twenty‐five control patients received sedatives that did not contain propylene glycol.Measurements and Main Results. Serum propylene glycol and lactate concentrations, osmolality, and basic metabolic profiles were obtained 72–108 hours after ICU admission. Clinical data, drug administration, and severity of illness scores were recorded. Osmol gap and the amount of propylene glycol administered before serum sampling predicted propylene glycol concentrations (r2=0.692, p2=0.532, pConclusion. Osmol gap can be used as a surrogate marker for serum propylene glycol concentration. In critically ill patients receiving lorazepam for sedation, an osmol gap above 10 was associated with concentrations previously reported to cause toxicity.


  • Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure

    by Brian J Barnes, Patricia A Howard

    OBJECTIVE: To evaluate the pharmacology, pharmacokinetics, safety, and clinical use of eplerenone in heart failure (HF). DATA SOURCES: English-language MEDLINE searches were performed from 1966 to May 2004. Key words included eplerenone, aldosterone receptor antagonist, heart failure, myocardial infarction, left-ventricular dysfunction, and cost-effectiveness. Additional references were identified from bibliographies of selected articles. STUDY SELECTION AND DATA EXTRACTION: Human trials evaluating the efficacy, safety, and cost-effectiveness of aldosterone receptor antagonists in HF were evaluated. DATA SYNTHESIS: Eplerenone is the first selective aldosterone receptor antagonist. The drug is indicated to improve the survival of stable patients with left-ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of HF following acute myocardial infarction. Efficacy and safety in this population have been demonstrated in a large, randomized clinical trial. Eplerenone is associated with severe and sometimes life-threatening hyperkalemia. Patients with reduced renal function and diabetes, as well as those on other drugs that increase potassium levels, are at highest risk. Eplerenone is metabolized by the cytochrome P450 system and may interact with drugs that interfere with this system. A major advantage of eplerenone over the nonselective aldosterone receptor antagonist spironolactone is lack of binding to progesterone and androgen receptors, which is associated with drug-induced gynecomastia, breast pain, and impotence. CONCLUSIONS: The addition of eplerenone to traditional HF therapy has been shown to reduce morbidity and mortality in patients who develop left-ventricular dysfunction after acute myocardial infarction. Eplerenone's selectivity reduces sex hormone—related adverse effects. Despite these benefits, the overall cost-effectiveness has yet to be determined.